CCM
Catalio Capital Management Portfolio holdings
AUM
$477M
This Quarter Return
-2.39%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$403M
AUM Growth
+$403M
(-12%)
Cap. Flow
-$24.4M
Cap. Flow
% of AUM
-6.05%
Top 10 Holdings %
Top 10 Hldgs %
69.57%
Holding
45
New
11
Increased
7
Reduced
7
Closed
9
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$21.3M |
| 2 |
Eli Lilly
LLY
|
$19.6M |
| 3 |
Inspire Medical Systems
INSP
|
$13.7M |
| 4 |
Becton Dickinson
BDX
|
$12.7M |
| 5 |
Soleno Therapeutics
SLNO
|
$11.5M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$28.2M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$24.8M |
| 3 |
Envista
NVST
|
$19.7M |
| 4 |
Exact Sciences
EXAS
|
$17.4M |
| 5 |
Masimo
MASI
|
$14.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Becton Dickinson
BDX
$55.3B
| $46.7M | 11.36% | 203,965 +55,350 | +37% | +$12.7M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $33.5M | 8.14% | 758,533 -6,135 | -0.8% | -$271K |
|
3
BridgeBio Pharma
BBIO
$9.89B
| $33.3M | 8.1% | 962,883 +64,425 | +7% | +$2.23M |
|
4
Edwards Lifesciences
EW
$47.8B
| $31.6M | 7.68% | 435,588 +102,444 | +31% | +$7.43M |
|
5
Ascendis Pharma
ASND
$11.8B
| $30.5M | 7.41% | 195,523 -20,064 | -9% | -$3.13M |
|
6
Cytokinetics
CYTK
$4.23B
| $23.5M | 5.73% | 585,812 +128,225 | +28% | +$5.15M |
|
7
Veracyte
VCYT
$2.39B
| $22.6M | 5.5% | 762,225 +271,678 | +55% | +$8.06M |
|
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $21.3M | 5.18% | +1,733,701 | New | +$21.3M |
|
|
9
Eli Lilly
LLY
$657B
| $19.6M | 4.76% | +23,682 | New | +$19.6M |
|
10
Intuitive Surgical
ISRG
$170B
| $18.1M | 4.4% | 36,499 -411 | -1% | -$204K |
|
11
LivaNova
LIVN
$3.08B
| $15M | 3.65% | 381,648 -130,799 | -26% | -$5.14M |
|
12
Dianthus Therapeutics
DNTH
$759M
| $13.8M | 3.37% | 763,471 | – | – |
|
|
13
Inspire Medical Systems
INSP
$2.77B
| $13.7M | 3.33% | +85,877 | New | +$13.7M |
|
14
Structure Therapeutics
GPCR
$1.11B
| $12.2M | 2.97% | 704,864 +135,469 | +24% | +$2.34M |
|
|
15
Soleno Therapeutics
SLNO
$3.6B
| $11.5M | 2.8% | +160,962 | New | +$11.5M |
|
16
uniQure
QURE
$896M
| $8.8M | 2.14% | 830,325 -71,648 | -8% | -$759K |
|
17
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.78M | 1.89% | +12,261 | New | +$7.78M |
|
|
SEPN
18
Septerna, Inc. Common Stock
SEPN
$539M
| $5.93M | 1.44% | 1,024,245 | – | – |
|
19
Protara Therapeutics
TARA
$120M
| $4.64M | 1.13% | 1,088,691 | – | – |
|
20
Adaptive Biotechnologies
ADPT
$2.01B
| $4.54M | 1.11% | +611,639 | New | +$4.54M |
|
21
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.48M | 1.09% | +114,616 | New | +$4.48M |
|
22
Keros Therapeutics
KROS
$618M
| $3.97M | 0.97% | 389,384 -17,908 | -4% | -$182K |
|
23
Vir Biotechnology
VIR
$686M
| $3.96M | 0.96% | +611,608 | New | +$3.96M |
|
24
Replimune Group
REPL
$422M
| $3.47M | 0.84% | +355,640 | New | +$3.47M |
|
|
ZBIO
25
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $2.33M | 0.57% | 295,148 +107,964 | +58% | +$853K |
|